

August 20, 2019



Oragenics, Inc. to Present Overview of Lantibiotics Pipeline at the Annual Military Health System Research Symposium

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM"), today announces it will be presenting a talk titled "Lantibiotics, a Novel Class of Antibiotics in the Pharmacopeia", which will be part of a session dedicated to novel antimicrobial developments to counter multidrug-resistant bacterial infections in military personnel. This talk will be presented on Thursday, August 22, 2019 at 8:30 AM ET at the annual Military Health System Research Symposium (MHSRS) held this year at the Gaylord Palms Resort & Convention Center, Kissimmee Fla.

The symposium is sponsored by the United States Department of Defense and is an invitation-only event for presenters. The presentation will provide an overview of the company's work with lantibiotics, specifically updates on the preclinical testing of OG716, our lead compound for the treatment of *C. difficile*, as well as new and exciting developments in our pipeline of lantibiotics.

"Our Lantibiotic program has tremendous potential to provide a unique approach to fighting antibiotic-resistant infections," stated Alan Joslyn, Ph.D., president and CEO of Oragenics, Inc. "We believe the opportunity to present to the Department of Defense represents further validation that our approach may be among those that provide the solution that modern medicine has been seeking. We look forward to sharing our data with this audience and discussing the implications for use in both military and civilian settings."

About MHSRS

The MHSRS is the Department of Defense's premier scientific meeting. It provides a venue for presenting new scientific knowledge resulting from military-unique research and development. The MHSRS is the only military or civilian meeting that focuses specifically on the unique medical needs of the Warfighter. Additional information about the MHSRS can be found at <https://mhsrs.amedd.army.mil/SitePages/Home.aspx>.

The MHSRS provides a collaborative setting for the exchange of information between military providers with deployment experience, research and academic scientists, international partners, and industry on research and related health care initiatives falling under the topic areas of Combat Casualty Care, Military Operational Medicine, Clinical and Rehabilitative Medicine, Medical Simulation and Information Sciences, Military Infectious Diseases and the Radiation Health Effects.

The MHSRS is an annual four-day educational symposium that draws approximately 2,900 attendees.

About Lantibiotics

Lantibiotics are a class of antibiotic compounds with novel mechanism of action, prized for their ability to overcome antibiotic-resistant infections. With resistant strains on the rise, particularly healthcare-acquired infections (HAI), the need for these potent lantibiotic agents is critical. Oragenics is pursuing the commercial-scale production of a lantibiotic for use as an antimicrobial.

About Oragenics, Inc.

We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries. The collaborations allow Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

For more information about Oragenics, please visit www.oragenics.com.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management's current views with respect to future events and performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission. Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20190820005286/en/>

Oragenics, Inc.

Corporate:

Michael Sullivan, 813-286-7900

Chief Financial Officer

msullivan@oragenics.com

or

Investors:

John Marco

Managing Director

CORE IR
310-819-2948
johnm@coreir.com

Media:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

Source: Oragenics, Inc.